Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CBX7 | O95931 | 1/20 | 0.34 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.34 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4419212 | 0.86 | HPGD (0.52) | HPGDMAPK1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4418860 | 0.86 | HPGD (0.52) | HPGDMAPK1SMN1; SMN2IDO1 | |
| SCHEMBL4416201 | 0.83 | HPGD (0.50) | HPGDMAPK1SMN1; SMN2IDO1MEN1 | |
| SCHEMBL4414415 | 0.83 | HPGD (0.50) | HPGDMAPK1SMN1; SMN2IDO1 | |
| SCHEMBL4413055 | 0.80 | HPGD (0.60) | HPGDMAPK1SMN1; SMN2 | |
| SCHEMBL4411792 | 0.78 | HPGD (0.50) | HPGDMAPK1SMN1; SMN2IDO1MEN1 | |
| SCHEMBL4417498 | 0.77 | HPGD (0.60) | HPGDMAPK1SMN1; SMN2IDO1 | |
| SCHEMBL4415842 | 0.74 | HPGD (0.52) | HPGDMAPK1SMN1; SMN2IDO1 | |
| SCHEMBL4413144 | 0.71 | HPGD (0.64) | HPGDMAPK1SMN1; SMN2IDO1MEN1 | |
| SCHEMBL4411794 | 0.71 | HPGD (0.64) | HPGDMAPK1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756071-B1 | BENZOXAZOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB PHARMA SA (BE) | 2009-08-26 | — | — | EP | claimed |
| US-20070299118-A1 | Benzoxazolone Derivatives, Processes For Preparing Them And Their Uses | UCB, S.A. (BE) | 2007-12-27 | — | — | US | claimed |
| EP-1756071-A1 | BENZOXAZOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2007-02-28 | — | — | EP | claimed |
| WO-2005118561-A1 | BENZOXAZOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2005-12-15 | — | — | WO | claimed |
| US-8293775-B2 | Benzoxazolone derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2012-10-23 | — | — | US | disclosed |
| EP-1756071-B1 | BENZOXAZOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB PHARMA SA (BE) | 2009-08-26 | — | — | EP | disclosed |
| US-20070299118-A1 | Benzoxazolone Derivatives, Processes For Preparing Them And Their Uses | UCB, S.A. (BE) | 2007-12-27 | — | — | US | disclosed |
| EP-1756071-A1 | BENZOXAZOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005118561-A1 | BENZOXAZOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299118-A1 | Benzoxazolone Derivatives, Processes For Preparing Them And Their Uses | PARK7, SNCA, GABRA5 | HPGD 232/4885MAPK1 3250/4885SMN1; SMN2 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.